Inrebic 100 mg hard capsules

DRUG2 trials

Sponsors

Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH, Martin-Luther-Universitaet Halle-Wittenberg

Conditions

Myeloproliferative neoplasm in accelerated phase (MPN-AP)Primary and secondary Myelofibrosis

Phase 1

Fedratinib in Combination with CC-486, a Hypomethylating Agent, in Patients with Accelerated Phase Myelofibrosis - FAMy

Active, not recruitingCTIS2024-519227-22-00

Martin-Luther-Universitaet Halle-WittenbergMyeloproliferative neoplasm in accelerated phase (MPN-AP)

Start: 2022-11-03Target: 44Updated: 2025-11-20

Phase 2

Phase II Study of Fedratinib and Nivolumab Combination in Patients with Myelofibrosis and Resistance or Suboptimal Response to JAK-inhibitor Treatment - The FRACTION Trial

CompletedCTIS2024-513953-64-00

Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbHPrimary and secondary Myelofibrosis

Start: 2022-06-23End: 2026-01-15Target: 30Updated: 2025-05-06